Efficacy and safety of statin treatment for hypercholesterolemia with chronic liver disease

Efficacy and safety of statin treatment for hypercholesterolemia with chronic liver disease - Efficacy and safety of statin treatment for hypercholesterolemia with chronic liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002011

Enrollment

Registered

2009-05-27

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic liver disease

Interventions

Pitavastatin 1-2mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Hypercholesterolemia (2)Chronic liver disease(NAFLD/NASH, hepatitis C) (3)Age 20 to 74 (4)Patients who received sufficient explanation and agreed with written informed consent

Exclusion criteria

Exclusion criteria: (1)Contraindication or relative contraindication of pitavastatin calcium. -Hypersensitivity for pitavastatin calcium -Serious hepatic disorder or biliary atresia -Receiving ciclosporin -Pregnant women, women suspected of being pregnant, or lactating women -Patients receiving fibrates who have abnormal laboratory test values about renal function (2)Women hoping to become pregnant during the study (3)Drug abuse, alcoholism (4)Patients judged to be inappropriate by the attending doctor

Design outcomes

Primary

Measure	Time frame
1.Change in AST, ALT, gammaGTP, ALP(for NAFLD, NASH) 2.Change in HCV RNA(for hepatitis C)	—

Countries

Japan

Contacts

Public ContactToshifumi Ohkusa

The Jikei University School of Medicine, Kashiwa Hospital Division of Gastroenterology and Hepatology

ohkusa@jikei.ac.jp04-7164-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026